The Primary Hyperoxaluria Type I drugs in development market research report provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria Type I, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary Hyperoxaluria Type I. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary Hyperoxaluria Type I and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Primary Hyperoxaluria Type I by seven companies/universities/institutes. The top development phase for Primary Hyperoxaluria Type I is preclinical with three drugs in that stage. The Primary Hyperoxaluria Type I pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Primary Hyperoxaluria Type I pipeline products market are: Alnylam Pharmaceuticals, Novo Nordisk and Biocodex.
The key targets in the Primary Hyperoxaluria Type I pipeline products market include 2 Hydroxyacid Oxidase 1, L-Lactate Dehydrogenase A Chain, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 3.
The key mechanisms of action in the Primary Hyperoxaluria Type I pipeline product include 2 Hydroxyacid Oxidase 1 Inhibitor with four drugs in Phase 0. The Primary Hyperoxaluria Type I pipeline products include three routes of administration with the top ROA being Subcutaneous and three key molecule types in the Primary Hyperoxaluria Type I pipeline products market including Gene Therapy, and Antisense RNAi Oligonucleotide.
Primary Hyperoxaluria Type I overview
Primary hyperoxaluria type 1 (PH1) is a rare disease that mainly affects the kidneys. “Primary” refers to being born with the disease, while hyperoxaluria refers to above normal levels of oxalate in the urine. PH1 is caused by genetic changes in a gene called AGXT. Signs and symptoms of PH1 vary in severity and may begin any time from infancy to early adulthood. Symptoms may include recurrent kidney stones, blood in the urine, and urinary tract infections.
For a complete picture of Primary Hyperoxaluria Type I’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
